Structural Insights into HCAR3 Agonist Selectivity via Cryo-EM

Study Background and Research Question

Hydroxycarboxylic acid receptors (HCARs), particularly HCAR2 and HCAR3 (also known as HM74A/GPR109A and GPR109B), are metabolite-sensing G-protein coupled receptors (GPCRs) central to the regulation of lipid metabolism and therapeutic strategies for dyslipidemia and related metabolic disorders. While HCAR2 agonists are clinically relevant, their use is often limited by adverse effects such as cutaneous flushing. In contrast, HCAR3 represents a promising alternative target, but the structural features underpinning its ligand recognition and selectivity have remained poorly defined. The central question addressed by Ye et al. (2025) is: What are the molecular determinants governing selective agonist binding to HCAR3 versus HCAR2, and how can this knowledge inform the development of next-generation hypolipidemic agents?

Key Innovation from the Reference Study

The primary innovation of the reference study lies in its presentation of high-resolution cryo-electron microscopy (cryo-EM) structures of HCAR3 in complex with several selective agonists, including (R)-5-methyl-4-oxo-5-phenyl-4,5-dihydrofuran-2-carboxylic acid (Acifran), compound 6O, D-phenyllactic acid, and IBC293. Complementary structures of HCAR2 bound to Acifran were also resolved. This multi-ligand, multi-receptor approach enabled the authors to delineate the key residues and conformational features that explain both ligand recognition and subtype selectivity—critical knowledge for the rational design of specific lipid metabolism regulators.

Methods and Experimental Design Insights

The researchers employed heterologous expression of HCAR3-Gi and HCAR2-Gi complexes in Sf9 cells, followed by purification and reconstitution suitable for single-particle cryo-EM. Four HCAR3-Gi complexes were visualized in the presence of different agonists, with resolutions ranging from 3.05 Å to 3.31 Å. The HCAR2-Gi complex with Acifran was resolved at 2.72 Å. The atomic coordinates and cryo-EM density maps for these complexes are publicly available in the Electron Microscopy Data Bank and Protein Data Bank. In addition to structural determination, ligand-induced GPCR activation was functionally validated by cAMP inhibition assays in HEK-293 cells. These assays confirmed the agonist activity and subtype selectivity observed in the cryo-EM studies, providing a robust functional-structural correlation.

Core Findings and Why They Matter

The high-resolution structures revealed several critical features:

• Agonist Binding Pocket Topology: The study identified that the orthosteric binding pocket of HCAR3 comprises distinct R1 and R2 subregions. Agonists with the capacity to fully occupy both regions, such as compound 6O, exhibit higher affinity due to increased contact surface.
• Determinants of Subtype Selectivity: Ligand selectivity between HCAR3 and HCAR2 was traced to a π–π stacking interaction with F107^3.32 in HCAR3 (versus L107^3.32 in HCAR2) and differences in binding pocket size dictated by residues V/L83^2.60, Y/N86^2.63, and S/W91^2.48. These subtle substitutions modulate both the chemical environment and spatial accommodation for ligands, accounting for differential agonist recognition.
• Acifran as a Structural Probe: Acifran ((R)-5-methyl-4-oxo-5-phenyl-4,5-dihydrofuran-2-carboxylic acid) was shown to engage both HCAR3 and HCAR2, but with unique interaction profiles at each receptor. The resolved structures provide a molecular blueprint for further optimization of hypolipidemic agents and selective probes for lipid metabolism research.
• Functional Implications: The combination of structural and cAMP assay data suggests that it is possible to engineer ligands with high HCAR3 selectivity, potentially avoiding the adverse effects associated with HCAR2 activation while maintaining efficacy in modulating lipid metabolism.

These insights directly inform the design of next-generation compounds for precise lipid signaling pathway modulation and metabolic disorder research.

Comparison with Existing Internal Articles

Several recent resources have highlighted the importance of selective HM74A/GPR109A and GPR109B agonists in lipid metabolism regulation. For example, Acifran: Selective HM74A/GPR109A Agonist for Lipid Metabo... underscores Acifran's utility as a high-purity tool compound for mechanistic studies, aligning with the structural revelations of the present study. Similarly, Acifran: Structural Insights and Next-Gen Assays in Lipid Metabolism Research discusses how cryo-EM advances are transforming the field, referencing Acifran’s role in enabling reproducible and mechanistically precise research workflows. The current reference study provides the atomic-level evidence that underpins these practical recommendations, clarifying exactly how Acifran and related agonists interact with their target receptors and guiding future assay and therapeutic development.

Limitations and Transferability

While the cryo-EM structures reported by Ye et al. represent a substantial advance, several limitations should be considered:

• System Context: The structural studies were performed in a detergent-solubilized, non-native membrane context using Sf9 insect cells, which may not fully recapitulate the dynamic environment of mammalian tissues.
• Agonist Diversity: Only a subset of potential endogenous and exogenous agonists were investigated. Broader screening would be needed to generalize the structural principles outlined.
• Translational Relevance: While the findings clarify molecular determinants of selectivity, in vivo validation remains necessary to confirm that the observed interactions translate to physiological outcomes and therapeutic index improvements.

Nevertheless, the structures provide a robust framework for the rational engineering of metabolic disorder research compounds and for designing assays that probe lipid metabolism regulation with higher precision.

Protocol Parameters

• HCAR3/HCAR2 expression: Use Sf9 insect cells with baculovirus-mediated transduction for high-yield receptor-Gi complex production as described in Ye et al. (2025).
• Agonist incubation: Incubate receptor-Gi complexes with 100–500 μM of selective agonist (e.g., Acifran or analogs) prior to cryo-EM grid preparation or downstream functional assays.
• Structural validation: Confirm ligand binding and receptor activation via cAMP inhibition assays in HEK-293 cells transfected with HCAR3/HCAR2 constructs.
• Ligand preparation: Prepare Acifran stock solutions (<21.82 mg/ml) in DMSO or ethanol; maintain at -20°C and use promptly to ensure compound integrity, as indicated in product information.

Research Support Resources

Researchers aiming to replicate or extend these workflows can utilize high-purity (R)-5-methyl-4-oxo-5-phenyl-4,5-dihydrofuran-2-carboxylic acid, such as Acifran (SKU B6848) from APExBIO, which is suitable for receptor-ligand interaction studies, lipid metabolism assays, and structural investigations. For comprehensive guidance on assay design and translational strategies, consult resources like Acifran: Structural Insights and Next-Gen Assays in Lipid Metabolism Research. Always adhere to recommended storage and handling practices to maintain reagent integrity and reproducibility.